The FDA decision on the expanded use of Vanda Pharmaceuticals Inc.’s (VNDA) Fanapt, proposed for the treatment of bipolar I disorder, is expected on April 2, 2024.Fanapt, an atypical antipsychotic, is already approved in the U.S. for the treatment of schizophrenia in adults.Though bipolar disorder and schizophrenia are both mental health conditions, they vary in the symptoms that define them. For example, bipolar disorder leads to fluctuations in mood, energy, and thinking while schizophrenia results in individuals appearing disconnected from reality. (Source: Medical New Today).The drug generated annual net product sales of $90.87 million in 2023, compared to $94.73 million in the prior year.VNDA is currently (Mar.28, 2024) trading at $4.00, up 2.87%.